
A low-cost mRNA vaccine, PTX-COVID19-B, was developed to address limited access to COVID-19 vaccines in poor countries. In a Phase 1 trial, the vaccine's safety, tolerability, and immunogenicity were evaluated in healthy adults. The trial included 60 participants who received two doses of different strengths of the vaccine. Few mild to moderate adverse events were observed, mainly localized pain and headache. All vaccinated participants developed antibodies against the Spike protein and showed neutralizing activity against the Wuhan strain as well as the Alpha, Beta, and Delta variants. The 40-µg dose exhibited fewer adverse reactions and was selected for a Phase 2 trial, currently ongoing.
Like
Save
Share